Michael D. Becker Appointed VP Investor Relations And Corporate Communications at Cytogen

Apr 09, 2001, 01:00 ET from Cytogen Corporation

    PRINCETON, N.J., April 9 /PRNewswire/ --
 Cytogen Corporation (Nasdaq:   CYTO) today announced that Michael D. Becker has
 joined the company as vice president, investor relations and corporate
 communications.
     For more than a decade, Michael D. Becker has been an influential analyst
 and commentator for the biotechnology industry.  Most recently, he was with
 Wayne Hummer Investments LLC, a Chicago-based regional brokerage firm, where
 he held senior positions as a biotechnology analyst, investment executive and
 portfolio manager.  Mr. Becker also served on the board of directors for the
 Chicago Biotech Network, a nonprofit trade association for the biotechnology
 industry in Illinois.  A nationally recognized spokesperson on issues in
 biotechnology, Mr. Becker has been featured in many of the nation's most
 influential business and healthcare media outlets.  He is also the founder and
 editor of "Beck on Biotech," a highly-regarded monthly biotechnology
 investment newsletter.
     "In products to treat prostate cancer and in researching the human body's
 protein interactions to develop new and more effective therapies for many
 other diseases, Cytogen is already an industry leader with significant
 potential.  I am very excited to be joining such a winning team," Mr. Becker
 said.
     "Michael Becker has an outstanding reputation in our industry, and we are
 very pleased that he will be joining Cytogen," said H. Joseph Reiser, Ph.D.,
 chief executive officer of Cytogen Corporation.  "He is the ideal professional
 to lead our efforts to communicate the exciting and often complex advances in
 our work in the years ahead.  He will be an important voice in our efforts to
 inform investors and the medical and patient communities about Cytogen's
 products, technology and business strategy."
 
     Cytogen Corporation is a biopharmaceutical company based in Princeton, NJ.
 The Company has two principal lines of business: a product-based oncology
 focus and a proteomics drug discovery platform.  Cytogen's expertise in
 monoclonal antibodies and molecular recognition are directed principally to
 the development of novel products for the diagnosis, imaging, staging and
 treatment of prostate cancer and a proteomics-driven drug discovery platform.
 For information regarding currently marketed products and general corporate
 information, visit www.cytogen.com.
 
     AxCell Biosciences, a subsidiary of Cytogen Corporation, is a leader in
 the effort to chart protein-signaling pathways in the human proteome as a
 means of discovering new drug targets.  AxCell is developing a proprietary
 protein-pathway database, the ProChart(TM) database as a discovery and
 development tool for subscribers in the pharmaceutical, biotechnology and
 agricultural industries.  For additional information on AxCell Biosciences,
 visit www.axcellbio.com.
 
 

SOURCE Cytogen Corporation
    PRINCETON, N.J., April 9 /PRNewswire/ --
 Cytogen Corporation (Nasdaq:   CYTO) today announced that Michael D. Becker has
 joined the company as vice president, investor relations and corporate
 communications.
     For more than a decade, Michael D. Becker has been an influential analyst
 and commentator for the biotechnology industry.  Most recently, he was with
 Wayne Hummer Investments LLC, a Chicago-based regional brokerage firm, where
 he held senior positions as a biotechnology analyst, investment executive and
 portfolio manager.  Mr. Becker also served on the board of directors for the
 Chicago Biotech Network, a nonprofit trade association for the biotechnology
 industry in Illinois.  A nationally recognized spokesperson on issues in
 biotechnology, Mr. Becker has been featured in many of the nation's most
 influential business and healthcare media outlets.  He is also the founder and
 editor of "Beck on Biotech," a highly-regarded monthly biotechnology
 investment newsletter.
     "In products to treat prostate cancer and in researching the human body's
 protein interactions to develop new and more effective therapies for many
 other diseases, Cytogen is already an industry leader with significant
 potential.  I am very excited to be joining such a winning team," Mr. Becker
 said.
     "Michael Becker has an outstanding reputation in our industry, and we are
 very pleased that he will be joining Cytogen," said H. Joseph Reiser, Ph.D.,
 chief executive officer of Cytogen Corporation.  "He is the ideal professional
 to lead our efforts to communicate the exciting and often complex advances in
 our work in the years ahead.  He will be an important voice in our efforts to
 inform investors and the medical and patient communities about Cytogen's
 products, technology and business strategy."
 
     Cytogen Corporation is a biopharmaceutical company based in Princeton, NJ.
 The Company has two principal lines of business: a product-based oncology
 focus and a proteomics drug discovery platform.  Cytogen's expertise in
 monoclonal antibodies and molecular recognition are directed principally to
 the development of novel products for the diagnosis, imaging, staging and
 treatment of prostate cancer and a proteomics-driven drug discovery platform.
 For information regarding currently marketed products and general corporate
 information, visit www.cytogen.com.
 
     AxCell Biosciences, a subsidiary of Cytogen Corporation, is a leader in
 the effort to chart protein-signaling pathways in the human proteome as a
 means of discovering new drug targets.  AxCell is developing a proprietary
 protein-pathway database, the ProChart(TM) database as a discovery and
 development tool for subscribers in the pharmaceutical, biotechnology and
 agricultural industries.  For additional information on AxCell Biosciences,
 visit www.axcellbio.com.
 
 SOURCE  Cytogen Corporation

RELATED LINKS

http://www.cytogen.com